



Atty. Dkt. No. 057491/0413

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Desmond MASCARENHAS
Title: NULL IGF FOR THE TREATMENT OF CANCER
Appl. No.: 09/399,120
Filing Date: 9/20/99
Examiner: Anish GUPTA
Art Unit: 1653

Handwritten signature and date 8/28/02

RECEIVED
AUG 23 2002
TECH CENTER 1600/2900

RESPONSE UNDER 37 C.F.R. §1.111

Commissioner for Patents
Washington, D.C. 20231

Sir:

This communication responds to an office action dated May 21, 2002, concerning the above-referenced patent application. By virtue of the accompanying petition and payment of extension fees, the present deadline for response is August 21, 2002. No other fees are believed due, but the PTO is authorized to invoice account No. 190741 for any charges deemed necessary. Please amend the application as follows:

In the Claims:

- C1*
7. (Amended) The method of claim 1, wherein the residue at position 60 of the amino acid sequence of said null IGF-I is altered to a non-aromatic residue.
8. (Amended) The method of claim 7, wherein the residue at position 24 or 31 of said amino acid sequence of said null IGF-I is additionally altered to a non-aromatic residue.

Please add the following new claims 18-44:

- C2*
18. (New) The method of claim 1, wherein the residue at position 60 of the amino acid sequence of said null IGF-I is altered to a leucine residue.
19. (New) The method of claim 1, wherein the residue at position 24 of the amino acid sequence of said null IGF-I is a non-aromatic residue.

08/22/2002 CNGUYEN 00000054 09399120

01 FC:103 08/29/2002 DWILLIA1 00000003 190741 09399120

01 FC:104 280.00 CH

002 876570 1

08/29/2002 DWILLIA1 00000002 190741 09399120
01 FC:103 108.00 CH